Trials / Completed
CompletedNCT00705042
Study Evaluating Enbrel Drug Levels in Healthy Male Chinese Subjects
A Randomized, Open-Label, Single-Dose Administration, Parallel-Group, Multisite Study of the Pharmacokinetics of Etanercept, 25 or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the Pharmacokinetics (PK) and safety and tolerability of etanercept, 25 and 50 mg, administered as a single dose to healthy male Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2008-09-01
- Completion
- 2008-11-01
- First posted
- 2008-06-25
- Last updated
- 2009-07-28
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00705042. Inclusion in this directory is not an endorsement.